Compare IDEXX Laboratories, Inc. (IDXX) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Sea Limited — how do they compare? IDEXX Laboratories, Inc. trades at $571.23 (market cap $46.22B), while Sea Limited trades at $127.59 (market cap $80.55B). The key difference: Sea Limited is the larger of the two by market cap, and Sea Limited is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | SE | |
|---|---|---|
Market Cap | $46.22B | $80.55B |
Sector | Health | Media |
52-Week High | $766.68 | $196.50 |
52-Week Low | $526.44 | $78.16 |
Enterprise Value | $47.12B | $75.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $595.76, up 1.55% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $4.27 versus $3.94 expected, driven by 9% organic revenue growth. The company raised full-year EPS guidance to $14.69–14.94, reflecting robust demand in companion animal diagnostics. Valuation ratios remain elevated with a P/E of 41.23, supported by high profitability margins including a net income margin of 25.03% and ROE of 74.21%.
Outlook is positive given consistent earnings beats, international expansion, and product innovation, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $683.33 implies 14.7% upside, with 57% of analysts rating it Buy. Investors should weigh growth durability against high multiples.
Sea Limited (SE) stock surged 12.11% to $128.7, driven by strong Q2 2026 results with revenue of $7.8 billion, up 48% year-over-year. The company demonstrated robust growth across e-commerce, fintech, and gaming segments, with net income rising 11% to $458 million. Technical indicators show a bullish trend, though RSI levels suggest overbought conditions. Analyst consensus remains positive with a $128.33 price target, supported by improved EBITDA guidance for Shopee.
The outlook for SE is favorable due to accelerating revenue growth and diversification, but risks include margin pressure from increased investments and credit costs. The stock's high P/E ratio of 50.78 demands sustained earnings expansion. Insider selling by the COO warrants monitoring. Overall, growth prospects outweigh near-term challenges, positioning SE for potential upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
